Cellebrite (CLBT) president awarded 423,550 RSUs vesting through 2030

Rhea-AI Filing Summary

Ramji Shiven reported acquisition or exercise transactions in this Form 4 filing.

Cellebrite DI Ltd. reported that President Products & Tech Ramji Shiven received a compensation grant of 423,550 restricted share units (RSUs), each representing one ordinary share when settled. Following this award, he holds 423,550 ordinary shares directly.

The RSUs vest over time: 105,898 vest on May 4, 2027, and 26,471 additional RSUs vest every three months through May 4, 2030, encouraging long-term retention and performance alignment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ramji Shiven

Role President Products & Tech

Type	Security	Shares	Price	Value
Grant/Award	Ordinary shares, par value NIS 0.00001	423,550	$0.00	--

Holdings After Transaction: Ordinary shares, par value NIS 0.00001 — 423,550 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 423,550 RSUs Grant price per share: $0.00 per share Initial vesting tranche: 105,898 RSUs +2 more

5 metrics

RSU grant size 423,550 RSUs Award of restricted share units to President Products & Tech

Grant price per share $0.00 per share Reported transaction price for RSU award

Initial vesting tranche 105,898 RSUs Vest on May 4, 2027

Subsequent quarterly vesting 26,471 RSUs Vest every three months through May 4, 2030

Shares after transaction 423,550 shares Total ordinary shares held directly after grant

Key Terms

restricted share units ("RSUs"), contingent right, Ordinary Share

3 terms

restricted share units ("RSUs") financial

"Represents an award of restricted share units ("RSUs") that will vest as follows"

contingent right financial

"Each RSU represents a contingent right to receive one Ordinary Share"

Ordinary Share financial

"Each RSU represents a contingent right to receive one Ordinary Share of the Issuer"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ramji Shiven

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President Products & Tech

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary shares, par value NIS 0.00001	05/12/2026		A		423,550(1)	A	$0	423,550	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted share units ("RSUs") that will vest as follows: 105,898 vest on May 4, 2027 and 26,471 vest every three months thereafter through May 4, 2030. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

Remarks:

	/s/ Shiven Ramji	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cellebrite (CLBT) disclose for Ramji Shiven?

Cellebrite disclosed that President Products & Tech Ramji Shiven received a grant of 423,550 restricted share units. These RSUs are part of his equity compensation and convert into ordinary shares over several years as they vest.

How many Cellebrite (CLBT) RSUs were granted to Ramji Shiven and at what price?

Ramji Shiven was granted 423,550 restricted share units with a reported grant price of $0.00 per share. This indicates a compensation award rather than a market purchase, with value realized as the RSUs vest into ordinary shares.

What is the vesting schedule for Ramji Shiven’s Cellebrite (CLBT) RSUs?

The award vests in tranches: 105,898 RSUs vest on May 4, 2027, and 26,471 RSUs vest every three months thereafter through May 4, 2030. Each vested RSU converts into one ordinary share upon settlement.

How many Cellebrite (CLBT) shares does Ramji Shiven hold after this Form 4 transaction?

After this RSU grant, Ramji Shiven is shown as directly holding 423,550 ordinary shares. This total reflects the reported position following the award and highlights his equity stake tied to Cellebrite’s future performance.

Is Ramji Shiven’s Cellebrite (CLBT) Form 4 transaction a purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market purchase. The transaction code A and price of $0.00 per share indicate an award of restricted share units provided by the company as part of executive compensation.